ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 819

Risks of Non-Cardiovascular Corticosteroid Related Adverse Events and Cancer in Giant Cell Arteritis: A  French Population-Based Cohort Study

Minh Phuong Do1, Grégory Pugnet2, Guillaume Moulis3, Gregory Guernec4, Maryse Lapeyre-Mestre5 and Laurent Sailler6, 1Faculté de Médecine, Toulouse University, Laboratoire de Pharmacoepidemiologie, Equipe émergente,UMR INSERM 1027, Toulouse, France, 2Department of Internal Medicine, Toulouse University Hospital, University of Toulouse, INSERM UMR 1027, Toulouse, France, 3Internal Medicine, Toulouse University Hospital, Toulouse, France, 4Faculté de Médecine, Toulouse University, UMR INSERM 1027, Toulouse, France, 5UMR 1027, INSERM-University of Toulouse, Toulouse, France, 6Medecine Interne, CHU Toulouse, Toulouse, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Adverse events, corticosteroids, Epidemiologic methods, giant cell arteritis and pharmacology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 5, 2017

Title: Vasculitis Poster I: Large Vessel Vasculitis

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Corticosteroid related adverse events are a main concern in patients suffering from giant cell arteritis. Conflicting results are reported on this topic, recurrent events are usually not taken into account and direct comparisons with the general population are scarce. We investigated non-cardiovascular corticosteroid related adverse events and cancer risks in an incident GCA patients cohort, the Midi-Pyrénées (southwest France) APOGEE cohort.

Methods:

APOGEE is an administrative database cohort of 103 incident GCA patients (median age : 77 [51-91] years ) and 606 age- and sex-matched controls included between January 2005 and December 2008. The risk of events was compared between patients and controls during the first 36 months of follow-up using Cox models for single events and a linear negative binomial regression model for multiple events (infections and hospitalizations). Generalized estimating equations were used to compare the risk of occurrence across 6-months time periods.

Results:

More than 1 Charlson comorbidity was present before diagnosis in 35% and 46,6% of GCA and control patients, respectively (p=0,03). The hazard ratios (HR) and incidence rate ratios (IRR) of main events are reported in table 1. The risk of any corticosteroid-related events was increased by 49.6% in GCA patients, but it was significant only during the 24 months following diagnosis of GCA. Recurrent (≥2) infections occurred in 61.2% of GCA patients versus 46.7% (p<0.001). The rate ratio of infections was increased and stable throughout the follow-up. Age over 75 years and sex were not significantly associated with the risk of infection but suffering ≥1 comorbidity was (IRR = 1.187, p<0.01). Infection was the main cause of hospitalization in GCA patients. The risk of hospitalization for any cause (excluding the first hospitalization corresponding to GCA diagnosis) was increased (50.5% vs 35,5%, p<0,001) and repeated hospitalizations were more frequent (p<0.001) in GCA patients. Presence of comorbidities was the sole independent predictor of the risk of hospitalization. The initial prednisone dose (<60 mg prednisone vs ≥ 60 mg/d) was not associated with the occurrence of any adverse event.

Conclusion:

Muskuloskeletal events were rare in the setting of osteoporosis prevention. Overall, the risk of serious (leading to hospitalization) or repeated infections is a concern. The increased risk of cancer was unexpected.

Table 1 : risk of new corticosteroid related events and cancer in GCA patients (compared to age and sex matched controls).

De novo events

p-value

HR, IC 95%

Cancer

<0.05

2.33 [1.03-5.22]

Diabetes mellitus

<0.01

2.60 [1.35-5.03]

Glaucoma

<0.001

2.41 [1.45-4.03]

Cataract (after 1 year)

<0.05

2.14 [1.08-4.23]

Cutaneous

<0.05

1.28 [1.01-1.63]

Neuropsychiatric

<0.01

1.48 [1.11-1.95]

Musculoskeletal

0.28

IRR , IC 95%

Infections

<0.05

1.27 [1.07-1.50]

Hospitalizations

<0.05

1.79 [1.26-2.53]


Disclosure: M. P. Do, None; G. Pugnet, None; G. Moulis, None; G. Guernec, None; M. Lapeyre-Mestre, None; L. Sailler, None.

To cite this abstract in AMA style:

Do MP, Pugnet G, Moulis G, Guernec G, Lapeyre-Mestre M, Sailler L. Risks of Non-Cardiovascular Corticosteroid Related Adverse Events and Cancer in Giant Cell Arteritis: A  French Population-Based Cohort Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/risks-of-non-cardiovascular-corticosteroid-related-adverse-events-and-cancer-in-giant-cell-arteritis-a-french-population-based-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risks-of-non-cardiovascular-corticosteroid-related-adverse-events-and-cancer-in-giant-cell-arteritis-a-french-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology